Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

INTRODUCTION: Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction. However, the impact of dose reductions on outcomes remains unclear and is mainly limited to...

Descripción completa

Detalles Bibliográficos
Autores principales: Thummalapalli, Rohit, Choudhury, Noura J., Ehrich, Fiona, Beardslee, Tyler, Brazel, Danielle, Zhang, Shannon S., Merchant, Shelby, Chen, Monica F., Heller, Glenn, Ramalingam, Suresh S., Ou, Sai-Hong Ignatius, Mileham, Kathryn F., Riely, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460990/
https://www.ncbi.nlm.nih.gov/pubmed/37644967
http://dx.doi.org/10.1016/j.jtocrr.2023.100546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460990/
https://www.ncbi.nlm.nih.gov/pubmed/37644967
http://dx.doi.org/10.1016/j.jtocrr.2023.100546

Ejemplares similares